Coronavirus disease is a major cause of severe damage to the lungs, and scientists now know the cause.
In fact, a specific macrophage in blood monocytes (the key cell for tissue functions) plays a role in the acute inflammatory response in the lungs affected by COVID.
This was revealed in a medical study in South Korea.
It is believed that COVID 19 has affected millions of people around the world, but most patients are hospitalized when the disease affects the lungs, for which the term code 19 pneumonia is used.
Research from the Korea Advanced Institute of Science and Technology found that in the early stages of COVID, lung tissue is affected first and a defense system is activated.
This initial and rapid response is called natural immunity, which is triggered by immune cells in the lungs.
Macrophages are one of the most important cells in this natural immune system of the lungs and macrophages in the bloodstream also play a role in the initial defense against viruses.
The researchers were examining the evolutionary stages of the immune response in a ferrite-coded lung in an animal ferrite and used the ferrite infection model for research.
The researchers analyzed 10 subtypes of macrophages over a 5-day period of coronavirus disease and discovered that macrophages formed by active monocytes not only clear the virus but also damage lung tissues.
Furthermore, they discovered that the inflammatory process of macrophages is similar to the immune response in the lung tissues of patients with severe coma.
The research team is currently working on a follow-up study to find a way to control the most severe cytokine stroma in patients with COVID.
The researchers said the analysis would help understand the early features of COVID 19 immunity and help identify components that suppress the immune response to target specific macrophages.
He said it was the first long-term study to use immune-coded lung cells.
The results of the study were published in the medical journal Nature Communications.
Earlier, a medical study conducted in the UK in May 2021 found that due to the severe severity of COVID 19, many of the patients undergoing treatment still experience adverse effects a year later.
A study by the University of Southampton found that one-third of hospital codes from Cowed had evidence of adverse effects in the lungs even after one year.
In a study published in the medical journal The Lancet Receptive Medicine, experts, along with experts from the Chinese city of Wuhan, examined patients with severe COVID 19 pneumonia and found out what their condition was a year later.
For this purpose, 83 patients were treated in the hospital who were suffering from severe severe pneumonia.
These patients were examined for 3, 6, 9 and 12 months, ie every 3 months they were examined.
During each examination, the lung function was examined along with the medical analysis, for which a CT scan was taken of the lungs and a walking test was also taken.
During the 12 months, most patients' symptoms improved with symptoms, exercise ability, and CT changes related to code 19.
A year later, most of the patients appeared to have fully recovered, but 5% were still having difficulty breathing.
One-third of patients' lung functions did not return to normal, especially the ability of the lungs to carry oxygen to the blood.
CT scans of a quarter of the patients revealed changes in some small parts of their lungs and this was common in people who had serious changes in their lungs while being treated in the hospital.
The researchers said that the majority of patients with severe pneumonia seem to fully recover, but some patients take several months to recover.
"Women have a higher rate of lung function than men and more research is needed to find out," she said.
"We still don't know what happens to patients after 12 months, so it's important to continue research," he said.
